irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical TrialJean‐Christophe Pignon, Sabina Signoretti, Kathleen M. Mahoney et al.|Clinical Cancer Research|2019Cited by 121